{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T19:40:32Z","timestamp":1733946032497,"version":"3.30.2"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.tracli.2022.02.004","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T16:12:45Z","timestamp":1644682365000},"page":"107-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study"],"prefix":"10.1016","volume":"29","author":[{"given":"Ushasree.","family":"Ravula","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasa Rao","family":"Chunchu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srujaleswari","family":"Mooli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pandu Ranga Rao","family":"Sarangapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2022.02.004_bib0110","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.tracli.2022.02.004_bib0115","doi-asserted-by":"crossref","first-page":"173451","DOI":"10.1016\/j.ejphar.2020.173451","article-title":"COVID-19: a review of the proposed pharmacological treatments","volume":"886","author":"Lam","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.tracli.2022.02.004_bib0120","doi-asserted-by":"crossref","first-page":"108790","DOI":"10.1016\/j.celrep.2021.108790","article-title":"Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2","volume":"34","author":"Gasser","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.tracli.2022.02.004_bib0125","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.tracli.2022.02.004_bib0130","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.4049\/jimmunol.2000840","article-title":"Discordance between serum neutralizing antibody titers and the recovery from COVID-19","volume":"205","author":"Ko\u00e7","year":"2020","journal-title":"J Immunol"},{"year":"2020","author":"US Food and Drug Administration","series-title":"Recommendations for investigational COVID-19 convalescent plasma","key":"10.1016\/j.tracli.2022.02.004_bib0135"},{"key":"10.1016\/j.tracli.2022.02.004_bib0140","doi-asserted-by":"crossref","first-page":"2000421","DOI":"10.2807\/1560-7917.ES.2020.25.16.2000421","article-title":"Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020","volume":"25","author":"Perera","year":"2020","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.tracli.2022.02.004_bib0145","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1038\/s41596-021-00536-y","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays","volume":"16","author":"Bewley","year":"2021","journal-title":"Nat Protoc"},{"key":"10.1016\/j.tracli.2022.02.004_bib0150","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jinf.2021.03.010","article-title":"Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay","volume":"82","author":"Murray","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.tracli.2022.02.004_bib0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13054-020-2818-6","article-title":"Treatment of COVID-19: old tricks for new challenges","volume":"24","author":"Cunningham","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.tracli.2022.02.004_bib0160","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3201\/eid2209.151164","article-title":"Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia","volume":"22","author":"Arabi Yaseen","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.tracli.2022.02.004_bib0165","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jac\/dkn243","article-title":"The management of coronavirus infections with particular reference to SARS","volume":"62","author":"Wong","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tracli.2022.02.004_bib0170","doi-asserted-by":"crossref","first-page":"100525","DOI":"10.1016\/j.eclinm.2020.100525","article-title":"Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma","volume":"26","author":"Maor","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.tracli.2022.02.004_bib0175","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/vox.12926","article-title":"Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?","volume":"115","author":"Tiberghien","year":"2020","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2022.02.004_bib0180","doi-asserted-by":"crossref","first-page":"e2035057","DOI":"10.1001\/jamanetworkopen.2020.35057","article-title":"SARS-CoV-2 transmission from people without COVID-19 symptoms","volume":"4","author":"Johansson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.tracli.2022.02.004_bib0185","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review","volume":"173","author":"Oran","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tracli.2022.02.004_bib0190","first-page":"103338","article-title":"Seroprevalence of SARS-CoV-2 IgG antibody among healthy blood donors: a single centre study","author":"Jaiswal","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.tracli.2022.02.004_bib0195","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(20)30544-1","article-title":"SARS-CoV-2 antibody seroprevalence in India, August\u2013September, 2020: findings from the second nationwide household serosurvey","volume":"9","author":"Murhekar","year":"2021","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.tracli.2022.02.004_bib0215","doi-asserted-by":"crossref","DOI":"10.1007\/s12288-021-01512-y","article-title":"SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India","author":"Chunchu","year":"2022","journal-title":"Indian Journal of Hematology and Blood Transfusion"},{"key":"10.1016\/j.tracli.2022.02.004_bib0200","first-page":"60","article-title":"Whole blood derived covid convalescent plasma: an economical option among developing countries","author":"Ravula","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.tracli.2022.02.004_bib0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103140","article-title":"Whole blood derived covid convalescent plasma: a practical experience from India","author":"Mandal","year":"2021","journal-title":"Transf Apher Sci"},{"key":"10.1016\/j.tracli.2022.02.004_bib0210","first-page":"1","article-title":"Convalescent plasma the old warhorse first to be inducted in pandemics is not the Zippy Chippy of Derby","author":"Sachdev","year":"2021","journal-title":"Indian J Hematol Blood Transfus"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782022000283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782022000283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T15:06:22Z","timestamp":1733843182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782022000283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1246782022000283"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2022.02.004","relation":{},"ISSN":["1246-7820"],"issn-type":[{"type":"print","value":"1246-7820"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2022.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}